8C5 Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Coherus Oncology Inc

Watchlist Manager

Watchlist

Price: 1.055 EUR -7.21%

Market Cap: €121m

C	Coherus Oncology Inc F:8C5	US
S	Scaling Capital 1 Corp XTSX:MATA	CA
T	Textron Inc F:TXT	US
N	Northrop Grumman Corp DUS:NTH	US
K	Koatsu Gas Kogyo Co Ltd TSE:4097	JP
H	Halozyme Therapeutics Inc F:RV7	US

Profitability Summary

Coherus Oncology Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

69%

Strong 3Y Average Gross Margin

55%

Gross Margin is Increasing

50% > 69%

Negative Operating Margin

-312%

Negative 3Y Average Operating Margin

-205%

Declining Operating Margin

-126% > -312%

Negative Net Margin

-259%

Strong 3Y Average Net Margin

55%

Declining Net Margin

-145% > -259%

Negative Free Cash Flow Margin

-365%

Negative 3Y Average Free Cash Flow Margin

-133%

Declining Free Cash Flow Margin

-135% > -365%

Negative ROE

-146%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-61%

Declining ROIC

-84% > -134%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.